Patents by Inventor Aneesh Karatt Vellatt

Aneesh Karatt Vellatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sodium channel inhibitors
    Patent number: 11932673
    Abstract: Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: March 19, 2024
    Assignee: MAXION THERAPEUTICS LIMITED
    Inventors: Aneesh Karatt Vellatt, John McCafferty, Sachin Badrinath Surade, Tim Luetkens, Edward William Masters, Michael Richard Dyson, Damian Colin Bell
  • POTASSIUM CHANNEL INHIBITORS
    Publication number: 20230331827
    Abstract: Abstract: Binding members for potassium channel Kv1.3 and their use in medicine, including for treatment of autoimmune conditions, metabolic disorders and obesity. Binding members comprise a fusion protein containing a Kv1.3-binding peptide, e.g., HsTx, ShK or KTX (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), paired with a partner domain (e.g., antibody variable domain).
    Type: Application
    Filed: July 11, 2018
    Publication date: October 19, 2023
    Applicant: MAXION THERAPEUTICS LIMITED
    Inventors: Aneesh KARATT VELLATT, John MCCAFFERTY, Sachin Badrinath SURADE, Tim LUETKENS, Edward William MASTERS, Michael Richard DYSON, Damian Colin BELL
  • SODIUM CHANNEL INHIBITORS
    Publication number: 20210179677
    Abstract: Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin (“donor diversity scaffold domain”) inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels.
    Type: Application
    Filed: July 11, 2018
    Publication date: June 17, 2021
    Applicant: IONTAS LIMITED
    Inventors: Aneesh KARATT VELLATT, John MCCAFFERTY, Sachin Badrinath SURADE, Tim LUETKENS, Edward William MASTERS, Michael Richard DYSON, Damian Colin BELL
  • Anti-CXCL12 antibody molecules and their uses
    Patent number: 10647766
    Abstract: Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 12, 2020
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Frances Rosemary Balkwill, John McCafferty, Gerard John Graham, Aneesh Karatt Vellatt, Peter Slavny
  • BINDING MEMBERS WITH ALTERED DIVERSITY SCAFFOLD DOMAINS
    Publication number: 20190256840
    Abstract: This invention relates to libraries of binding members that each comprise a fusion protein which contains a donor diversity scaffold domain, such as a cysteine rich protein, inserted within a recipient diversity scaffold domain, such as an antibody constant or variable domain. Libraries and methods of generating libraries are provided, along with screening methods, binding members and methods of using the binding members.
    Type: Application
    Filed: January 9, 2017
    Publication date: August 22, 2019
    Applicant: IONTAS LTD
    Inventors: Aneesh Karatt Vellatt, John McCafferty, Sachin Surade, Tim Luetkens, Edward Masters, Michael Dyson
  • Anti-CXCL12 Antibody Molecules and Their Uses
    Publication number: 20170362314
    Abstract: Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 21, 2017
    Inventors: Frances Rosemary Balkwill, John McCafferty, Gerard John Graham, Aneesh Karatt Vellatt, Peter Slavny